CY1109070T1 - Διαδερμικη μορφη δοσολογιας περιλαμβανουσα ενα δραστικο παραγοντα και ενα αλας και μια μορφη ελευθερης βασεως ενος ανταγωνιστη - Google Patents

Διαδερμικη μορφη δοσολογιας περιλαμβανουσα ενα δραστικο παραγοντα και ενα αλας και μια μορφη ελευθερης βασεως ενος ανταγωνιστη

Info

Publication number
CY1109070T1
CY1109070T1 CY20091100516T CY091100516T CY1109070T1 CY 1109070 T1 CY1109070 T1 CY 1109070T1 CY 20091100516 T CY20091100516 T CY 20091100516T CY 091100516 T CY091100516 T CY 091100516T CY 1109070 T1 CY1109070 T1 CY 1109070T1
Authority
CY
Cyprus
Prior art keywords
salt
interderative
free
animal
pharmaceutically acceptable
Prior art date
Application number
CY20091100516T
Other languages
English (en)
Inventor
Ihor Shevchuk
Bruce Reidenberg
Original Assignee
Euro-Celtique S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro-Celtique S.A. filed Critical Euro-Celtique S.A.
Publication of CY1109070T1 publication Critical patent/CY1109070T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7092—Transdermal patches having multiple drug layers or reservoirs, e.g. for obtaining a specific release pattern, or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η παρούσα εφεύρεση αναφέρεται σε μία ανθεκτική σε παρέμβαση διαδερμική μορφή δοσολογίας περιλαμβάνουσα ένα δραστικό παράγοντα, όπως ένα οπιούχο, ή ένα φαρμακευτικά αποδεκτό άλας του, μία ελεύθερη βάση ενός αντίθετου παράγοντα, όπως ενός οπιούχου ανταγωνιστή, και ένα φαρμακευτικά αποδεκτό άλας ενός αντίθετου παράγοντα, όπως ενός οπιούχου ανταγωνιστή. Η διαδερμική μορφή δοσολογίας επιτρέπει τη διαδερμική χορήγηση μίας αποτελεσματικής ποσότητας του δραστικού παράγοντα ή ενός φαρμακευτικά αποδεκτού άλατος του σε ένα ζώο. Η εφεύρεση αναφέρεται περαιτέρω σε μεθόδους για την αγωγή ή την πρόληψη του πόνου σε ένα ζώο περιλαμβάνουσες την επαφή του δέρματος ενός ζώου το οποίο την έχει ανάγκη με τη διαδερμική μορφή δοσολογίας της εφευρέσεως επί χρονικό διάστημα επαρκές για την αγωγή ή την πρόληψη του πόνου.
CY20091100516T 2002-08-20 2009-05-14 Διαδερμικη μορφη δοσολογιας περιλαμβανουσα ενα δραστικο παραγοντα και ενα αλας και μια μορφη ελευθερης βασεως ενος ανταγωνιστη CY1109070T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40498002P 2002-08-20 2002-08-20
EP03749093A EP1530469B1 (en) 2002-08-20 2003-08-20 Transdermal dosage form comprising an active agent and a salt and free-base form of an antagonist

Publications (1)

Publication Number Publication Date
CY1109070T1 true CY1109070T1 (el) 2014-07-02

Family

ID=31946794

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20091100516T CY1109070T1 (el) 2002-08-20 2009-05-14 Διαδερμικη μορφη δοσολογιας περιλαμβανουσα ενα δραστικο παραγοντα και ενα αλας και μια μορφη ελευθερης βασεως ενος ανταγωνιστη

Country Status (12)

Country Link
US (1) US20040126323A1 (el)
EP (1) EP1530469B1 (el)
JP (3) JP4642467B2 (el)
AT (1) ATE423560T1 (el)
AU (1) AU2003268144A1 (el)
CY (1) CY1109070T1 (el)
DE (1) DE60326354D1 (el)
DK (1) DK1530469T3 (el)
ES (1) ES2323127T3 (el)
PT (1) PT1530469E (el)
SI (1) SI1530469T1 (el)
WO (1) WO2004017941A2 (el)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60336394D1 (de) * 2002-04-23 2011-04-28 Durect Corp Transdermale analgetische systeme mit reduziertem missbrauchspotential
US7524515B2 (en) * 2003-01-10 2009-04-28 Mutual Pharmaceuticals, Inc. Pharmaceutical safety dosage forms
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
AR047936A1 (es) * 2003-04-30 2006-03-15 Purdue Pharma Ltd Forma de dosificacion transdermica resistente a la manipulacion
US20040219195A1 (en) * 2003-04-30 2004-11-04 3M Innovative Properties Company Abuse-resistant transdermal dosage form
US8790689B2 (en) * 2003-04-30 2014-07-29 Purdue Pharma L.P. Tamper resistant transdermal dosage form
US7182955B2 (en) * 2003-04-30 2007-02-27 3M Innovative Properties Company Abuse-resistant transdermal dosage form
US7867511B2 (en) 2004-01-23 2011-01-11 Travanti Pharma Inc. Abuse potential reduction in abusable substance dosage form
LT2351555T (lt) * 2004-02-23 2016-12-27 Euro-Celtique S.A. Piktnaudžiavimui atspari priemonė, skirta transderminiam opoido įvedimui
DE102004019916A1 (de) * 2004-04-21 2005-11-17 Grünenthal GmbH Gegen Missbrauch gesichertes wirkstoffhaltiges Pflaster
WO2006023644A2 (en) * 2004-08-20 2006-03-02 3M Innovative Properties Company Transdermal drug delivery device with translucent protective film
US7827983B2 (en) * 2004-12-20 2010-11-09 Hewlett-Packard Development Company, L.P. Method for making a pharmaceutically active ingredient abuse-prevention device
EP1865978A4 (en) 2005-03-21 2012-01-25 Univ Columbia NEW NEURONAL PAINWAY
TWI366460B (en) 2005-06-16 2012-06-21 Euro Celtique Sa Cannabinoid active pharmaceutical ingredient for improved dosage forms
JP2007037868A (ja) * 2005-08-05 2007-02-15 Transcutaneous Technologies Inc 経皮投与装置及びその制御方法
JPWO2007026671A1 (ja) * 2005-08-29 2009-03-05 Ｔｔｉ・エルビュー株式会社 センサからの情報により投与すべき薬剤の選定を行うイオントフォレーシス装置
CN101316602B (zh) 2005-09-27 2015-06-03 组织技术公司 羊膜制品和纯化的组合物及其使用方法
US8187639B2 (en) * 2005-09-27 2012-05-29 Tissue Tech, Inc. Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment
US20070071807A1 (en) * 2005-09-28 2007-03-29 Hidero Akiyama Capsule-type drug-releasing device and capsule-type drug-releasing device system
US20070078445A1 (en) * 2005-09-30 2007-04-05 Curt Malloy Synchronization apparatus and method for iontophoresis device to deliver active agents to biological interfaces
WO2007070632A2 (en) * 2005-12-13 2007-06-21 Biodelivery Sciences International, Inc. Abuse resistant transmucosal drug delivery device
WO2008022128A2 (en) * 2006-08-14 2008-02-21 Shire Pharmaceuticals, Inc. Transdermal delivery of meptazinol
TW200800223A (en) * 2005-12-21 2008-01-01 Shire Pharmaceuticals Inc Transdermal delivery of meptazinol
US7740879B2 (en) * 2006-01-17 2010-06-22 Harrogate Holdings Abuse resistant transdermal drug delivery patch
US8846742B2 (en) 2006-02-14 2014-09-30 The Trustees Of Columbia University In The City Of New York Neuronal pain pathway modulators
JP5064391B2 (ja) * 2006-07-14 2012-10-31 久光製薬株式会社 貼付剤
AU2007275581B2 (en) 2006-07-21 2011-09-08 Biodelivery Sciences International, Inc. Transmucosal delivery devices with enhanced uptake
BRPI0719353A2 (pt) 2006-12-01 2014-01-07 Titi Ellebeau Inc Sistemas, dispositivos e métodos para dispositivos de energização e/ou controle, por exemplo, dispositivos de distribuição transdérmicos
DE102007021549A1 (de) * 2007-05-08 2008-11-13 Novosis Ag Transdermales therapeutisches System enthaltend mindestens zwei Opioide
MX2009012273A (es) * 2007-05-18 2010-04-09 Tti Ellebeau Inc Dispositivos de suministro transd?rmico que aseguran la liberaci?n mejorada de un principio activo a trav?s de una interfaz biol?gica.
WO2009106831A2 (en) 2008-02-28 2009-09-03 Syntropharma Limited Pharmaceutical composition
TWI541246B (zh) 2008-12-08 2016-07-11 歐陸斯迪公司 二氫羥戊甲嗎啡
US9175066B2 (en) 2009-04-24 2015-11-03 Tissuetech, Inc. Compositions containing HC-HA complex and methods of use thereof
US9277748B2 (en) 2010-03-12 2016-03-08 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Agonist/antagonist compositions and methods of use
US9526770B2 (en) 2011-04-28 2016-12-27 Tissuetech, Inc. Methods of modulating bone remodeling
EP2717888B1 (en) 2011-06-10 2020-09-09 Tissuetech, Inc. Methods of processing fetal support tissues
WO2013026064A1 (en) 2011-08-18 2013-02-21 Biodelivery Sciences International, Inc. Abuse-resistant mucoadhesive devices for delivery of buprenorphine
KR20140068058A (ko) 2011-09-30 2014-06-05 테이코쿠 팔마 유에스에이, 인코포레이티드 경피 패치 처리 시스템
US9901539B2 (en) 2011-12-21 2018-02-27 Biodelivery Sciences International, Inc. Transmucosal drug delivery devices for use in chronic pain relief
GB201309654D0 (en) 2013-05-30 2013-07-17 Euro Celtique Sa Method
PL3096746T3 (pl) * 2014-01-22 2019-09-30 4P Therapeutics Systemy transdermalne zapobiegające nadużywaniu i niewłaściwemu użyciu
TW201603818A (zh) 2014-06-03 2016-02-01 組織科技股份有限公司 組成物及方法
US10071090B2 (en) 2014-07-18 2018-09-11 Buzzz Pharmaceuticals Limited Oxymorphone transdermal patch
US10010543B1 (en) 2014-12-23 2018-07-03 Barr Laboratories, Inc. Transdermal dosage form
US20160243288A1 (en) 2015-02-23 2016-08-25 Tissuetech, Inc. Apparatuses and methods for treating ophthalmic diseases and disorders
US20160287835A1 (en) * 2015-04-02 2016-10-06 Nogina, LLC Method for treating angina
TWI720984B (zh) 2015-05-20 2021-03-11 美商帝聖工業公司 用於防止上皮細胞增生及上皮-間質轉移之組合物及方法
EP3352823B1 (en) * 2015-09-24 2021-04-21 Pain Therapeutics, Inc. Crystalline salts of naloxone and naltrexone
US12551509B2 (en) 2015-11-18 2026-02-17 Lucina Patent Holdco, Llc Acellular regenerative products and methods of their manufacture
TW201733600A (zh) 2016-01-29 2017-10-01 帝聖工業公司 胎兒扶持組織物及使用方法
ES3001152T3 (es) 2016-12-20 2025-03-04 Lts Lohmann Therapie Systeme Ag Sistema terapéutico transdérmico que contiene asenapina y polisiloxano o poliisobutileno
PL3338768T3 (pl) * 2016-12-20 2020-05-18 Lts Lohmann Therapie-Systeme Ag Transdermalny system terapeutyczny zawierający asenapinę
WO2019002204A1 (en) 2017-06-26 2019-01-03 Lts Lohmann Therapie-Systeme Ag TRANSDERMAL THERAPEUTIC SYSTEM CONTAINING ASENAPINE AND SILICONE-TYPE ACRYLIC HYBRID POLYMER
TWI795446B (zh) * 2017-10-04 2023-03-11 美商神經治療股份有限公司 右旋美索芬(dextromethorphan)經皮輸送裝置
CN111447927A (zh) * 2017-12-08 2020-07-24 帝国制药美国公司 纳洛酮经皮给药装置及其使用方法
US11389844B2 (en) 2018-03-20 2022-07-19 Verde Environmental Technologies, Inc. Blister pack disposal system
EP3810099A1 (en) 2018-06-20 2021-04-28 LTS Lohmann Therapie-Systeme AG Transdermal therapeutic system containing asenapine
AU2019291060B2 (en) 2018-06-20 2024-09-05 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
WO2020008366A1 (en) 2018-07-02 2020-01-09 Clexio Biosciences Ltd. Transdermal dosage form
WO2020009685A1 (en) 2018-07-02 2020-01-09 John Tang Transdermal dosage form
WO2020008370A1 (en) 2018-07-02 2020-01-09 Clexio Biosciences Ltd. Transdermal patch
WO2020188496A1 (en) * 2019-03-18 2020-09-24 Moshe Rogosnitzky Stable liquid naltrexone compositions
US12364692B2 (en) 2020-02-14 2025-07-22 Teikoku Pharma Usa, Inc. Topical naloxone compositions and methods for using the same
USD1094727S1 (en) 2022-07-16 2025-09-23 Aso Llc Transdermal toe patch
USD1077245S1 (en) 2022-07-16 2025-05-27 Aso Llc Transdermal foot patch
USD1097178S1 (en) 2022-07-16 2025-10-07 Aso Llc Transdermal foot patch

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3527864A (en) * 1966-11-18 1970-09-08 Procter & Gamble Compositions for topical application to animal tissue and method of enhancing penetration thereof
US3472931A (en) * 1969-01-17 1969-10-14 Foster Milburn Co Percutaneous absorption with lower alkyl amides
US3903256A (en) * 1972-02-07 1975-09-02 Procter & Gamble Compositions for topical application of animal tissue and method of enhancing penetration thereof
US3896238A (en) * 1972-04-05 1975-07-22 Procter & Gamble Dermatological compositions
US3952099A (en) * 1973-03-13 1976-04-20 The Procter & Gamble Company Dermatological compositions
US4046886A (en) * 1975-01-17 1977-09-06 The Procter & Gamble Company Dermatological compositions
US4316893A (en) * 1975-06-19 1982-02-23 Nelson Research & Development Co. Vehicle composition containing 1-substituted azacycloalkan-2-ones
US4405616A (en) * 1975-06-19 1983-09-20 Nelson Research & Development Company Penetration enhancers for transdermal drug delivery of systemic agents
US3989816A (en) * 1975-06-19 1976-11-02 Nelson Research & Development Company Vehicle composition containing 1-substituted azacycloheptan-2-ones
US4130667A (en) * 1976-01-12 1978-12-19 The Procter & Gamble Company Dermatological compositions
US4060084A (en) * 1976-09-07 1977-11-29 Alza Corporation Method and therapeutic system for providing chemotherapy transdermally
US4335115A (en) * 1976-11-01 1982-06-15 The Procter & Gamble Company Anti-acne composition
US4299826A (en) * 1979-10-12 1981-11-10 The Procter & Gamble Company Anti-acne composition
US4379454A (en) * 1981-02-17 1983-04-12 Alza Corporation Dosage for coadministering drug and percutaneous absorption enhancer
US4343798A (en) * 1981-06-23 1982-08-10 The Procter & Gamble Company Topical antimicrobial anti-inflammatory compositions
US4560553A (en) * 1981-07-07 1985-12-24 Merck & Co., Inc. Use of eucalyptol for enhancing skin permeation of bio-affecting agents
US4626539A (en) * 1984-08-10 1986-12-02 E. I. Dupont De Nemours And Company Trandermal delivery of opioids
JPS61103840A (ja) * 1984-10-26 1986-05-22 Nitto Electric Ind Co Ltd 外皮投与用組成物
US4806341A (en) * 1985-02-25 1989-02-21 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration
US5066648A (en) * 1985-11-29 1991-11-19 Merck & Co., Inc. Pyroglutamic acid esters used as dermal penetration enhancers for drugs
US4863970A (en) * 1986-11-14 1989-09-05 Theratech, Inc. Penetration enhancement with binary system of oleic acid, oleins, and oleyl alcohol with lower alcohols
US4940586A (en) * 1987-02-26 1990-07-10 Alza Corporation Skin permeation enhancer compositions using sucrose esters
US4746515A (en) * 1987-02-26 1988-05-24 Alza Corporation Skin permeation enhancer compositions using glycerol monolaurate
US4879275A (en) * 1987-09-30 1989-11-07 Nelson Research & Development Co. Penetration enhancers for transdermal delivery of systemic agent
US5474783A (en) * 1988-03-04 1995-12-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5164406A (en) * 1988-06-02 1992-11-17 Bristol-Myers Squibb Co. Method for enhancing transdermal penetration and compositions useful therein
US5641504A (en) * 1988-06-09 1997-06-24 Alza Corporation Skin permeation enhancer compositions using glycerol monolinoleate
US5378730A (en) * 1988-06-09 1995-01-03 Alza Corporation Permeation enhancer comprising ethanol and monoglycerides
US4960771A (en) * 1988-07-12 1990-10-02 Rajadhyaksha Vithal J Oxazolidinone penetration enhancing compounds
US5236714A (en) * 1988-11-01 1993-08-17 Alza Corporation Abusable substance dosage form having reduced abuse potential
EP0387751B1 (en) * 1989-03-15 1994-06-08 Nitto Denko Corporation Medicated plasters
US4973468A (en) * 1989-03-22 1990-11-27 Cygnus Research Corporation Skin permeation enhancer compositions
US5240711A (en) * 1989-11-29 1993-08-31 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Transdermal therapeutic system comprising as active component buprenorphine
US5069909A (en) * 1990-06-20 1991-12-03 Cygnus Therapeutic Systems Transdermal administration of buprenorphine
US5227169A (en) * 1991-05-17 1993-07-13 Theratech, Inc. Sorbitan esters as skin permeation enhancers
US5326566A (en) * 1991-05-17 1994-07-05 Bristol-Myers Squibb Company Use of dibutyl adipate and isopropyl myristate in topical and transdermal products
US5149538A (en) * 1991-06-14 1992-09-22 Warner-Lambert Company Misuse-resistive transdermal opioid dosage form
US5238933A (en) * 1991-10-28 1993-08-24 Sri International Skin permeation enhancer compositions
US5229130A (en) * 1991-12-20 1993-07-20 Cygnus Therapeutics Systems Vegetable oil-based skin permeation enhancer compositions, and associated methods and systems
CA2097163C (en) * 1992-06-01 2002-07-30 Marianna Foldvari Topical patch for liposomal drug delivery system
US5308625A (en) * 1992-09-02 1994-05-03 Cygnus Therapeutic Systems Enhancement of transdermal drug delivery using monoalkyl phosphates and other absorption promoters
US6162456A (en) * 1992-09-24 2000-12-19 Ortho-Mcneil Pharmaceutical, Inc. Adhesive transdermal drug delivery matrix of a physical blend of hydrophilic and hydrophobic polymers
EP0721349A1 (en) * 1993-09-29 1996-07-17 Alza Corporation Monoglyceride/lactate ester permeation enhancer for oxybutynin
US5420106A (en) * 1994-03-22 1995-05-30 Bristol-Myers Squibb Company Method and composition having enhanced alpha-hydroxy acid skin permeation and retention
US5540934A (en) * 1994-06-22 1996-07-30 Touitou; Elka Compositions for applying active substances to or through the skin
US5882676A (en) * 1995-05-26 1999-03-16 Alza Corporation Skin permeation enhancer compositions using acyl lactylates
US5785991A (en) * 1995-06-07 1998-07-28 Alza Corporation Skin permeation enhancer compositions comprising glycerol monolaurate and lauryl acetate
US5834468A (en) * 1995-07-07 1998-11-10 Zeneca Limited Substituted aryl and heteroaryl compounds as E-type prostaglandin antagonists
US5902603A (en) * 1995-09-14 1999-05-11 Cygnus, Inc. Polyurethane hydrogel drug reservoirs for use in transdermal drug delivery systems, and associated methods of manufacture and use
US5837289A (en) * 1996-07-23 1998-11-17 Grasela; John C. Transdermal delivery of medications using a combination of penetration enhancers
US5985317A (en) * 1996-09-06 1999-11-16 Theratech, Inc. Pressure sensitive adhesive matrix patches for transdermal delivery of salts of pharmaceutical agents
AU4990797A (en) * 1996-10-24 1998-05-15 Alza Corporation Permeation enhancers for transdermal drug delivery compositions, devices, and methods
JP2001503749A (ja) * 1996-10-30 2001-03-21 セラテック・インコーポレーテッド 透過促進剤としてのグリコール酸の脂肪酸エステル及びその塩
US5968547A (en) * 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
US5804215A (en) * 1997-03-21 1998-09-08 L. Perrigo Company Transdermal patch disposal system and method
DK1685839T3 (da) * 1997-12-22 2013-06-24 Euro Celtique Sa Farmaceutisk oral doseringsform omfattende en kombination af en opioidagonist og opioidantagonist
CN1204890C (zh) * 1997-12-22 2005-06-08 欧罗赛铁克股份有限公司 防止阿片样物质滥用的方法
US20040033253A1 (en) * 2002-02-19 2004-02-19 Ihor Shevchuk Acyl opioid antagonists

Also Published As

Publication number Publication date
US20040126323A1 (en) 2004-07-01
JP2006501241A (ja) 2006-01-12
JP2011021029A (ja) 2011-02-03
WO2004017941A2 (en) 2004-03-04
JP2010163446A (ja) 2010-07-29
JP5329461B2 (ja) 2013-10-30
ES2323127T3 (es) 2009-07-07
ATE423560T1 (de) 2009-03-15
SI1530469T1 (sl) 2009-06-30
DK1530469T3 (da) 2009-05-04
JP5437214B2 (ja) 2014-03-12
EP1530469B1 (en) 2009-02-25
EP1530469A2 (en) 2005-05-18
DE60326354D1 (de) 2009-04-09
JP4642467B2 (ja) 2011-03-02
WO2004017941A3 (en) 2004-04-22
AU2003268144A1 (en) 2004-03-11
PT1530469E (pt) 2009-05-19
AU2003268144A8 (en) 2004-03-11

Similar Documents

Publication Publication Date Title
ATE423560T1 (de) Transdermale dosierungsform enthaltend einen wirkstoff und einen antagonisten in freier base und in salz form
ATE392892T1 (de) Missbrauchssichere transdermale opioid- verabreichungsvorrichtungen
CY1107262T1 (el) Θεραπεια της εξαρτησης στερησης
ATE401874T1 (de) Verabreichung von capsaicinoiden
DE602004028841D1 (de) Purin nucleoside für die behandlung von durch flavividrae verursachten krankheiten, einschliesslich hepatitis c
ATE375341T1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
NO20006604L (no) Fremgangsmåter og transdermale sammensetninger for lindring av smerte
WO2004039325A3 (en) Treatment of pain with jnk inhibitors
Cordery et al. Simultaneous transdermal delivery of buprenorphine hydrochloride and naltrexone hydrochloride by iontophoresis
CY1107352T1 (el) Προεγχειρητικη θεραπευτικη αγωγη μετεγχειρητικου πονου
ATE310509T1 (de) Methode zur behandlung eines analgesiebedürftigen patienten
DE60325965D1 (de) Für die behandlung bzw. prevention von schmerzen geeignete triazaspiroverbindungen
ATE487480T1 (de) Perhexilin zur behandlung von chronischer herzinsuffizienz
DE60004833D1 (de) Paracetamol und buspiron enthaltende pharmazeutische zusammensetzung mit analgetischer wirkung
UA26886C2 (uk) Солі 1,3-діарил-4,5-поліметилеhімідазолію, що виявляють аhальгезуючу активhість
TH60393A (th) การบัดบัดรักษาอาการเจ็บปวด
FR2812549B1 (fr) Associations dalfopristine/quinupristine avec le cefpirome